Full Press Release Details
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer.
ALXO
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
Key Takeaway: ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
Price reaction · baseline $7.76 (2023-02-15 close) · hit after-hours · clean, no other ALXO news in the window
day 0 close · peak
-3.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)